{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:03:00Z","timestamp":1792202580742,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer is one of the most common cancer types worldwide. Generally, research relies on invasive sampling strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we generate bladder cancer organoids directly from urine (urinoids). In this project, we establish 12 urinoid lines from 22 patients with non-muscle and muscle-invasive bladder tumours, with an efficiency of 55%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The histopathological features of the urinoids accurately resemble those of the original bladder tumours. Genetically, there is a high concordance of single nucleotide polymorphisms (92.56%) and insertions &amp; deletions (91.54%) between urinoids and original tumours from patient 4. Furthermore, these urinoids show sensitivity to bladder cancer drugs, similar to their tissue-derived organoid counterparts. Genetic analysis of longitudinally generated tumoroids and urinoids from one patient receiving systemic immunotherapy, identify alterations that may guide the choice for second-line therapy. Successful treatment adaptation was subsequently demonstrated in the urinoid setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Therefore, urinoids can advance precision medicine in bladder cancer as a non-invasive platform for tumour pathogenesis, longitudinal drug-response monitoring, and therapy adaptation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-023-02494-6","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:03:00Z","timestamp":1702638180000},"page":"369-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation"],"prefix":"10.1038","volume":"130","author":[{"given":"Bastiaan J.","family":"Viergever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle A. E.","family":"Raats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Mullenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy N.","family":"Jonges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-7881","authenticated-orcid":false,"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan H.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-4390","authenticated-orcid":false,"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7982","authenticated-orcid":false,"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"2494_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","DOI":"10.3322\/caac.21654"},{"key":"2494_CR2","doi-asserted-by":"crossref","unstructured":"Chen C, Hu L, Chen Y, Hou J. The prognostic value of histological subtype in patients with metastatic bladder cancer. Oncotarget. 2017;8:28408. Available from www.impactjournals.com\/oncotarget.","DOI":"10.18632\/oncotarget.16083"},{"key":"2494_CR3","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines. Eur Urol. 2021;79:82\u2013104.","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"2494_CR4","doi-asserted-by":"crossref","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"2494_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle\u2010invasive bladder cancer: a systematic review and two\u2010step meta\u2010analysis. Oncologist. 2016;21:708\u201315.","journal-title":"Oncologist"},{"key":"2494_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.eururo.2014.05.006","volume":"66","author":"DJ McConkey","year":"2014","unstructured":"McConkey DJ, Choi W, Dinney CPN. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol. 2014;66:609\u201310. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.006.","journal-title":"Eur Urol"},{"key":"2494_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","volume":"69","author":"FH Groenendijk","year":"2016","unstructured":"Groenendijk FH, De Jong J, Fransen Van De Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384\u20138.","journal-title":"Eur Urol"},{"key":"2494_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4:1140\u201353.","journal-title":"Cancer Discov"},{"key":"2494_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610814000348.","journal-title":"Cancer Cell"},{"key":"2494_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2009.08.115","volume":"183","author":"SF Shariat","year":"2010","unstructured":"Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68\u201375. https:\/\/doi.org\/10.1016\/j.juro.2009.08.115.","journal-title":"J Urol"},{"key":"2494_CR11","doi-asserted-by":"crossref","unstructured":"Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315.","DOI":"10.1038\/nature12965"},{"key":"2494_CR12","doi-asserted-by":"crossref","unstructured":"Lopez\u2010beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L. Molecular classification of bladder urothelial carcinoma using nanostring\u2010based gene expression analysis. Cancers. 2021;13:5500.","DOI":"10.3390\/cancers13215500"},{"key":"2494_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11291-0","volume":"7","author":"MBH Thomsen","year":"2017","unstructured":"Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep. 2017;7:1\u20139.","journal-title":"Sci Rep"},{"key":"2494_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle invasive bladder cancer. Cell. 2017;171:540\u201356.","journal-title":"Cell"},{"key":"2494_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, H\u00f8yer S, Ulh\u00f8i BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27\u201342.","journal-title":"Cancer Cell"},{"key":"2494_CR16","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel H, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci USA. 2019;116:4567\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2494_CR17","doi-asserted-by":"crossref","unstructured":"Xu T, Junge JA, Delfarah A, Lu YT, Arnesano C, Iqbal M, et al. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep. 2022;12:5518.","DOI":"10.1038\/s41598-022-09438-9"},{"key":"2494_CR18","doi-asserted-by":"crossref","unstructured":"Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017;8:2193.","DOI":"10.1038\/s41467-017-02320-7"},{"key":"2494_CR19","doi-asserted-by":"crossref","unstructured":"Thomas J, Sonpavde G. Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers. 2022;14:1795.","DOI":"10.3390\/cancers14071795"},{"key":"2494_CR20","doi-asserted-by":"crossref","unstructured":"Mossanen M, Carvalho FLF, Muralidhar V, Preston MA, Reardon B, Conway JR, et al. Genomic features of muscle-invasive bladder cancer arising after prostate radiotherapy. Eur Urol. 2022;81:466\u201373.","DOI":"10.1016\/j.eururo.2021.12.004"},{"key":"2494_CR21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.conb.2012.02.005","volume":"22","author":"M Eiraku","year":"2012","unstructured":"Eiraku M, Sasai Y. Self-formation of layered neural structures in three-dimensional culture of ES cells. Curr Opin Neurobiol. 2012;22:768\u201377.","journal-title":"Curr Opin Neurobiol"},{"key":"2494_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39:1190\u2013201.","journal-title":"Cancer Cell"},{"key":"2494_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165:1586\u201397.","journal-title":"Cell"},{"key":"2494_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"key":"2494_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41588-019-0399-6","volume":"51","author":"ACF Bolhaqueiro","year":"2019","unstructured":"Bolhaqueiro ACF, Ponsioen B, Bakker B, Klaasen SJ, Kucukkose E, van Jaarsveld RH, et al. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nat Genet. 2019;51:824\u201334. https:\/\/doi.org\/10.1038\/s41588-019-0399-6.","journal-title":"Nat Genet"},{"key":"2494_CR26","doi-asserted-by":"crossref","unstructured":"Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343.","DOI":"10.3389\/fphar.2020.00343"},{"key":"2494_CR27","doi-asserted-by":"crossref","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141.","DOI":"10.1016\/j.xinn.2021.100141"},{"key":"2494_CR28","doi-asserted-by":"crossref","unstructured":"Kaufmann O, Volmerig J, Dietel M. Anatomic pathology\/DETECTION OF UROPLAKIN III Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. J Clin Pathol. 2000;113. https:\/\/academic.oup.com\/ajcp\/article\/113\/5\/683\/1757785.","DOI":"10.1309\/PYQC-17CB-063T-Q07J"},{"key":"2494_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1309\/AJCP1J0JPJBPSUXF","volume":"142","author":"W Li","year":"2014","unstructured":"Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014;142:864\u201371.","journal-title":"Am J Clin Pathol"},{"key":"2494_CR30","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26:1839\u201344.","journal-title":"Nat Med"},{"key":"2494_CR31","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/sj.onc.1207260","volume":"23","author":"CD Hurst","year":"2004","unstructured":"Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004;23:2250\u201363.","journal-title":"Oncogene"},{"key":"2494_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0165-4608(93)90131-5","volume":"70","author":"R Schapers","year":"1993","unstructured":"Schapers R, Smeets W, Hopman A, Pauwels R, Geraedts J, Ramaekers F. Heterogeneity in bladder cancer as detected by conventional chromosome analysis and interphase cytogenetics. Cancer Genet Cytogenet. 1993;70:56\u201361.","journal-title":"Cancer Genet Cytogenet"},{"key":"2494_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578:112\u201321.","journal-title":"Nature"},{"key":"2494_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature09460","volume":"467","author":"PJ Campbell","year":"2011","unstructured":"Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Erin D, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2011;467:1109\u201313.","journal-title":"Nature"},{"key":"2494_CR35","doi-asserted-by":"crossref","unstructured":"Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, et al. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell. 2020;183:197\u2013210.e32.","DOI":"10.1016\/j.cell.2020.08.006"},{"key":"2494_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"SV Williams","year":"2013","unstructured":"Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795.","journal-title":"Hum Mol Genet"},{"key":"2494_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0302-2838(03)00056-3","volume":"43","author":"K Kawamura","year":"2003","unstructured":"Kawamura K, Moriyama M, Shiba N, Ozaki M, Tanaka T, Nojima T, et al. Centrosome hyperamplification and chromosomal instability in bladder cancer. Eur Urol. 2003;43:505\u201315.","journal-title":"Eur Urol"},{"key":"2494_CR38","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1126\/science.1210214","volume":"333","author":"A Janssen","year":"2011","unstructured":"Janssen A, Van Der Burg M, Szuhai K, Kops GJPL, Medema RH. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science. 2011;333:1895\u20138.","journal-title":"Science"},{"key":"2494_CR39","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.xgen.2022.100112","volume":"2","author":"C Shale","year":"2022","unstructured":"Shale C, Cameron DL, Baber J, Wong M, Cowley MJ, Papenfuss AT, et al. Unscrambling cancer genomes via integrated analysis of structural variation and copy number. Cell Genomics. 2022;2:100112.","journal-title":"Cell Genomics"},{"key":"2494_CR40","doi-asserted-by":"crossref","unstructured":"Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:7333.","DOI":"10.1038\/nature09744"},{"key":"2494_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","volume":"153","author":"SC Baca","year":"2013","unstructured":"Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666\u201377.","journal-title":"Cell"},{"key":"2494_CR42","doi-asserted-by":"crossref","unstructured":"Pihan GA. Centrosome dysfunction contributes to chromosome instability, chromoanagenesis, and genome reprograming in cancer. Front Oncol. 2013;3:277.","DOI":"10.3389\/fonc.2013.00277"},{"key":"2494_CR43","doi-asserted-by":"crossref","unstructured":"Anderson ND, De Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, et al. Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science. 2018;361:eaam8419.","DOI":"10.1126\/science.aam8419"},{"key":"2494_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrclinonc.2017.198","volume":"15","author":"L Sansregret","year":"2018","unstructured":"Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018;15:139\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"2494_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10555-013-9427-7","volume":"32","author":"HH Heng","year":"2013","unstructured":"Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY, et al. Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Metastasis Rev. 2013;32:325\u201340.","journal-title":"Cancer Metastasis Rev"},{"key":"2494_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-854","volume":"14","author":"N Bonberg","year":"2014","unstructured":"Bonberg N, Pesch B, Behrens T, Johnen G, Taeger D, Gawrych K, et al. Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study. BMC Cancer. 2014;14:1\u201310.","journal-title":"BMC Cancer"},{"key":"2494_CR47","doi-asserted-by":"crossref","unstructured":"Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68:959\u201367.","DOI":"10.1016\/j.eururo.2015.07.009"},{"key":"2494_CR48","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","volume":"29","author":"S Ding","year":"2022","unstructured":"Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. 2022;29:905\u201317.e6.","journal-title":"Cell Stem Cell"},{"key":"2494_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7169","volume":"6","author":"B Majumder","year":"2015","unstructured":"Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:1\u201314.","journal-title":"Nat Commun"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02494-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:04:40Z","timestamp":1707123880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02494-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,24]]}},"alternative-id":["2494"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02494-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bladder cancer patients from the University Medical Center Utrecht were invited to participate in this prospective proof-of-concept project by means of informed consent by the treating urologist or the nurse practitioner. Human bladder tissue was obtained from the University Medical Center Utrecht (UMCU). Ethical approval was granted by the Biobank Research Ethics Committee (TCBio) of the UMCU. Written informed consent was obtained from all patients involved in this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BV: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. DR: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. VG, JE, TJ and JM declare no competing interests. MH: Research support from Bristol-Myers Squibb, AstraZeneca, Roche and 4SC; consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seagen, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). OK: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. RM: Advisory role (institutional): Merck, MSD, Janssen, Bristol-Myers Squibb. Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}